Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 48Prostatic Neoplasms, Castration-Resistant 3Adenocarcinoma 3Urogenital Neoplasms 2Salivary Gland Neoplasms 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Neoplasms 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Male Urogenital Diseases 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Diseases 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Neoplasms by Site 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1Genital Diseases, Male 1Fatigue 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3relugolix 2luprolide acetate gel depot 2enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiosurgery 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1gallium 68 PSMA-11 1darolutamide 1abiraterone 1X-Rays 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radium-223 1Radiotherapy, Image-Guided 1Radiation Dose Hypofractionation 1Proton Therapy 1Prednisone 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × darolutamide × 1 year × Clear all
NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡